Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

IL-2, regulatory T cells, and tolerance.

Brad H Nelson1

  • 1Deeley Research Centre, British Columbia Cancer Agency, Victoria, British Columbia, Canada. bnelson@bccancer.bc.ca

Journal of Immunology (Baltimore, Md. : 1950)
|March 23, 2004
PubMed
Summary

Interleukin-2 (IL-2) was thought to boost T cell immunity, but it actually limits immune responses. IL-2 is crucial for regulatory T cells that maintain self-tolerance, impacting immune therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CRI-CCTG-0003/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021).

Cancer treatment and research communications·2026
Same author

Rethinking ovarian cancer III: the past decade and future directions.

Nature reviews. Cancer·2026
Same author

Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Nature communications·2026
Same author

Multidimensional Characterization of Tumor-Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes.

Cancer discovery·2026
Same author

Copper ionophores drive divergent responses to immune checkpoint inhibition across colorectal tumor models.

Cancer letters·2026
Same author

Phenotypic Characterization and Prognostic Impact of CD103+ Tissue-Resident Memory T Cells in Diffuse Large B-cell Lymphoma.

Cancer immunology research·2025

Area of Science:

  • Immunology
  • Molecular Biology
  • Cell Biology

Background:

  • Interleukin-2 (IL-2) is a cytokine historically recognized as a T cell growth factor.
  • Clinical applications of IL-2 aimed to enhance T cell immunity for cancer and AIDS.
  • Blocking antibodies against the IL-2 receptor (IL-2R) were used to suppress immune responses in transplantation.

Purpose of the Study:

  • To resolve the paradox between IL-2's assumed role in enhancing and its observed role in limiting T cell responses.
  • To elucidate the primary physiological function of IL-2 in vivo.
  • To re-evaluate clinical strategies for manipulating the IL-2 pathway based on new biological insights.

Main Methods:

  • Studies in mouse models investigating the effects of IL-2 pathway disruption.
  • Analysis of lymphoid hyperplasia and autoimmune phenotypes.
  • Investigation of the role of IL-2 in the development and expansion of specific T cell subsets.

Main Results:

  • Disruption of the IL-2 pathway in mice led to lymphoid hyperplasia and autoimmunity, not immune deficiency.
  • IL-2 was found to be essential for the development and peripheral expansion of CD4(+)CD25(+) regulatory T cells.
  • Regulatory T cells were identified as key mediators of IL-2's immunosuppressive function and maintenance of self-tolerance.

Conclusions:

  • The primary physiological role of IL-2 is to limit T cell responses, primarily through its action on regulatory T cells.
  • IL-2 is critical for maintaining self-tolerance by suppressing potentially harmful T cell activity.
  • A revised understanding of IL-2 biology necessitates re-evaluation of its clinical manipulation for immune modulation.

Related Experiment Videos